NCT01677884

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)

Conditions

• Colorectal Neoplasms

Interventions

Type	Name	Description
DRUG	Bevacizumab	Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
DRUG	Capecitabine	Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
DRUG	Irinotecan	Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)

Timeline

• Start date: 2012-11-01
• Primary completion: 2016-02-01
• Completion: 2016-02-01
• First posted: 2012-09-03
• Last updated: 2016-06-09

Locations

1 site across 1 country: France